



Biotech Daily

Tuesday August 30, 2022

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH UP: EMVISION UP 12%; MICRO-X DOWN 9%**
- * **CLINUVEL REVENUE UP 38% TO \$67m, PROFIT DOWN 15.6% TO \$21m**
- * **COGSTATE REVENUE UP 38% TO \$65m, PROFIT UP 84% TO \$15.5m**
- * **ALCIDION REVENUE UP 33% TO \$34.4m, LOSS UP 97% TO \$4.4m**
- * **IMEX H1 REVENUE UP 83% TO \$9.5m, LOSS DOWN 37% TO \$1.7m**
- * **IDT REVENUE DOWN 24% TO \$12m, PROFIT TO \$1.2m LOSS**
- * **MICRO-X REVENUE UP 138% TO \$9m, LOSS UP 16% TO \$17m**
- * **GENETIC TECHNOLOGIES REVENUE \$6.8m, LOSS UP 1% TO \$7.1m**
- * **MEDLAB REVENUE DOWN 13.5% TO \$3.8m, LOSS DOWN 42% TO \$7.2m**
- * **CSIRO PANDEMIC PREPAREDNESS REPORT**
- * **RESAPP REVENUE \$2.5m, LOSS UP 5% TO \$7.1m**
- * **MEDICAL DEVELOPMENTS RETAIL RIGHTS RAISE \$10m; TOTAL \$30m**
- * **TOTAL BRAIN: SONDERMIND \$2.5m LOAN**
- * **JAPAN PATENT FOR IMMUTEP IMP321 (EFTI)**
- * **PATRY'S: PAT-DX1 PASSES ENGINEERING SPECIFICATIONS**
- * **PERENNIAL REDUCES TO 7.4% OF LUMOS**
- * **REGAL INCREASES, DILUTED TO 18% IN OPTHEA**
- * **PARADIGM: VALE KEVIN HOLLINGSWORTH; ABBY MACNISH CO SEC**
- * **JAN WEST TO REPLACE IMPEDIMED DIRECTOR JUDITH DOWNES**
- * **CYNATA APPOINTS JANINE ROLFE DIRECTOR**

MARKET REPORT

The Australian stock market was up 0.47 percent on Tuesday August 30, 2022, with the ASX200 up 32.8 points to 6,998.3 points. Nineteen of the Biotech Daily Top 40 stocks were up, 14 fell, six traded unchanged and one was untraded.

Emvision was the best, up 17 cents or 12.1 percent to \$1.58, with 38,279 shares traded. Imugene, Orthocell and Patrys climbed four percent or more; Alcidion and Pro Medicus were up more than three percent; Actinogen, Impedimed, Nova Eye, Prescient and Uscom rose two percent or more; Avita, Cochlear, Immutep, Pharmaxis and Universal Biosensors were up more than one percent; with Clinuvel, Neuren, Proteomics, Resmed and Telix up by less than one percent.

Micro-X led the falls, down 1.25 cents or 9.4 percent to 12 cents, with 732,764 shares traded. Compumedics lost 5.45 percent; Atomo fell three percent; Antisense, Genetic Signatures, Medical Developments, Nanosonics, Oncosil, Opthea, Polynovo and Volpara shed more than one percent; Oncosil and Opthea were down more than one percent; with CSL, Mesoblast, Paradigm and Starpharma down by less than one percent.

CLINUVEL PHARMACEUTICALS

Clinuvel says revenue for the year to June 30, 2022 was up 38.25 percent to \$66,987,000 with net profit after tax down 15.6 percent to \$20,876,000.

The company said revenue came from sales of its Scenesse treatment for erythropoietic protoporphyria (EPP) in the US and Europe.

Clinuvel chief financial officer Darren Keamy said that "improved cash inflows this year have further bolstered the company's cash reserves enabling us to continue the implementation of a growth strategy in the face of difficult economic headwinds".

Clinuvel said it would pay an unfranked dividend of 4.0 cents a share to holders on the record date of September 7 to be paid on September 21, 2022, up 1.5 cent on 2021.

The company said diluted earnings per share was down 16.7 percent to 40.3 cents, with net tangible assets up 31.0 percent to \$2.504, with cash and cash equivalents of \$121,509,282 at June 30, 2022 compared to \$82,690,982 at June 30, 2021.

Clinuvel was up one cent or 0.1 percent to \$17.36 with 181,099 shares traded.

COGSTATE

Cogstate says revenue for the year to June 30, 2022 was up 37.6 percent to \$US44,980,356 (\$A65,385,038) with net profit after tax up 83.7 percent to \$US10,692,600 (\$A15,543,142).

The company said revenue from its cognition testing software included \$US40,328,147 in clinical trials, \$US4,456,700 from healthcare and \$US195,509 from research revenue.

Cogstate that "record contract sales, combined with contracted revenue at the beginning of the financial year, resulted in \$US45 million revenue for the financial year and profit before tax of \$US10.7 million - both record results".

Cogstate said it expected 2022-'23 revenue to be consistent and targeted earnings before interest, taxation, depreciation and amortization (Ebitda) at 27 to 29 percent of revenue.

Cogstate said diluted earnings per share rose 41.7 percent to 4.35 US cents, net tangible asset backing per share was up 181.0 percent to 10.34 US cents, with cash of \$US30,597,170 at June 30, 2022 compared to \$US23,640,789 at June 30, 2021.

Cogstate fell 9.5 cents or 5.6 percent to \$1.60.

ALCIDION GROUP

Alcidion says that revenue for the year to June 30, 2022 was up 32.7 percent to \$34,355,000 with net loss after tax up 96.6 percent to \$4,412,000.

Alcidion said revenue came from sales of its hospital management and patient care software in the UK, New Zealand, and Australia.

The company said that “an increase in staff costs was consistent with the strategy of scaling key resourcing, which was delayed from 2020-'21, particularly in the UK, to take advantage of emerging opportunities”.

Alcidion said that included in the loss was \$2,136,000 related to the acquisition of Silverlink PCS Software Limited and \$1,248,000 of amortization related to acquired intangibles as well as \$328,000 of non-cash share-based payment expense.

Alcidion said that diluted loss per share was up 72.7 percent from 0.22 cents to 0.38 cents, with net tangible assets per share turned from 1.7 cents to negative 0.4 cents.

The company said it had cash and cash equivalents of \$17,339,000 at June 30, 2022, compared to \$25,027,000 at June 30, 2021.

Alcidion was up half a cent or 3.3 percent to 15.5 cents with 2.8 million shares traded.

IMEX HEALTH SERVICES

Imex says revenue for the six months to June 30, 2022 was up 83.4 percent to \$9,461,648 with net loss after tax down 37.2 percent to \$1,744,063.

The company said \$9,150,875 of revenue came from leasing of its equipment, internet-based Aquila radiology platform, and software and services, with the remaining revenue of \$310,773 from medical licences, and service of equipment and software.

Imex chief executive officer Dr German Arango said his company was “taking a definitive pathway to achieve profitability based on a cost reduction plan, maintaining existing recurrent revenues, and bringing new customers”.

Imex said diluted loss per share was down 42.3 percent to 5.31 cents, with net tangible assets per share down 23.8 percent to 19.07 cents.

The company said it had cash and cash equivalents of \$856,065 at June 30, 2022 compared to \$8,342,337 at June 30, 2021.

Imex was up four cents or 7.9 percent to 54.5 cents.

IDT AUSTRALIA

IDT says revenue for the year to June 30, 2022 was down 24.1 percent to \$12,130,000 with last year's \$2,103,000 profit turned to a loss after tax of \$1,160,000.

The company said revenue came primarily from drug and marijuana manufacturing, particularly the manufacture of active pharmaceutical ingredients.

IDT chair Alan Fisher and chief executive officer Dr David Sparling said the company faced Covid-19 related impacts, and that its process to establish an mRNA manufacturing facility with the Federal Government was unsuccessful.

“In contrast to the first half of the reporting period, IDT has not been able to gain further traction in the second half of the year with its sovereign manufacturing initiatives,” Mr Fisher and Dr Sparling said.

IDT said last year's 0.9 cents diluted earnings turned to a diluted loss per share of 0.5 cents, with net tangible asset backing per share unchanged from last year's 11 cents.

The company said that it had cash and cash equivalents of \$9,214,000 at June 30, 2022 compared to \$6,928,000 at June 30, 2021.

IDT fell one cent or 7.4 percent to 12.5 cents.

MICRO-X

Micro-X says that revenue for the 12 months to June 30, 2022, was up 138.0 percent to \$8,970,000 with net loss after tax up 16.0 percent to \$17,089,000.

The company said the revenue came from its mobile hospital and defence x-ray products. Micro-X chair David Knox said his company faced difficulty due to “instability in the stock market driven by supply constraints from China and the war in Ukraine, along with rising inflation and interest rates”.

Mr Knox said that sales growth was driven by “successfully [delivering] milestones with our Department of Homeland Security contracts” and a “strong presence in Seattle ... led by our manager of airport security, to drive connections with US customers and technology partners”.

The company said diluted loss per share rose 0.3 percent to 3.71 cents, net tangible asset backing per share was down 43.8 percent to 4.15 cents per share.

Micro-X said it had cash and equivalents of \$10,303,000 at June 30, 2022 compared to \$30,135,000 at June 30, 2021.

Micro-X fell 1.25 cents or 9.4 percent to 12 cents.

GENETIC TECHNOLOGIES

Genetic Technologies says it has returned to significant revenue of \$6,794,816 for the year to June 30, 2022, with net loss after tax up 0.75 percent to \$7,130,998.

Genetic Technologies said the increase of revenue from \$120,554 to \$6,794,816 was “mainly due to sales of Easydna direct-to-consumer genetic tests” and that other revenue was from sales of its Genetype tests for breast and colorectal cancer.

In August last year, the company said it had acquired Esaydna for \$US4 million (\$A5.5 million) in cash and scrip on August 13, 2021 (BD: Aug 16, 2021).

Today, Genetic Technologies said diluted loss per share was unchanged from last year’s 0.8 cents, with net tangible asset per share down 50.0 percent to 0.12 cents.

Genetic Technologies said it had cash and cash equivalents of \$11,731,325 at June 30, 2022, compared to \$20,902,282 at June 30, 2021.

Genetic Technologies was unchanged at 0.4 cents with 12.9 million shares traded.

MEDLAB CLINICAL

Medlab says revenue for the year to June 30, 2022 was down 13.5 percent to \$3,803,741 with net loss after tax down 41.9 percent to \$7,162,433.

The company said revenue came primarily from \$1,282,434 in sales of its pharmaceutical products and \$2,521,307 in sales from its discontinued nutraceutical (food additive) products.

Medlab chief executive officer Dr Sean Hall said that “despite Covid related issues ... the company’s programs are progressing well, we have strong line of sight on markets, impact and pricing capabilities, our partnering is thorough, well diverse and more success is expected”.

Medlab said diluted loss per share fell 24.9 percent to \$3.65, with net tangible assets per share down 91.2 percent to 2.28 cents.

The company said it had cash and equivalents of \$5,191,031 at June 30, 2022, compared to \$13,434,762 at June 30, 2021.

Medlab fell 10 cents or 0.75 percent to \$13.20.

COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION

The Commonwealth Scientific and Industrial Research Organisation says Australia can improve its resilience to pandemics, reduce their economic impact and protect people. The CSIRO said that its 'Strengthening Australia's Pandemic Preparedness' report "highlights six science and technology areas critical to minimizing the impact of pandemics in Australia ... and makes 20 recommendations that could reduce impacts while improving economic, social and health outcomes".

The report is available at: <https://www.csiro.au/pandemic>.

The CSIRO said that "six key science and technology areas identified" to prepare for future pandemics were: pre-clinical capabilities for vaccines, therapeutics and diagnostics enabling faster development; on-shore vaccine manufacturing across a diverse range of vaccine technologies, ensuring vaccine supply; therapeutics repurposing and novel antivirals; point-of-care diagnostics for case identification; genomic analysis of pathogens and their variants; and data sharing for informing response strategies.

The Organisation said that the report shows how a more efficient and technology-enabled health system could act as an infectious disease early warning system, allow new treatments to be developed and deployed quickly, let patients be diagnosed and treated sooner, ensure the security of our vaccine supply, and better inform decision-making. CSIRO chief executive Dr Larry Marshall said preparing and protecting the nation from pandemics would take a team approach.

"Australia played a critical role in the global response to Covid-19 to contain outbreaks and find a vaccine, including detection, safety, data tracking, vaccine manufacture and testing, virus analysis, and predictive data analytics," Dr Marshall said.

"As infectious disease continues to grow in frequency and impact, science can prepare us for what's ahead as well as drive our recovery and resilience to protect our people and secure our future prosperity," Dr Marshall said.

The report said that five virus families were likely to cause future pandemics: coronaviridae, flaviviridae such as Dengue fever, orthomyxoviridae including influenza, paramyxoviridae and togaviridae such as Chikungunya fever.

The CSIRO said that the report was based on consultations with 146 experts from 66 organizations across government, industry, and the research sector.

The Organisation said that science and technology could complement effective, short-term strategies such as lockdowns, border closures and quarantine approaches while mitigating their significant social, health and economic costs.

The CSIRO said that Covid-19 pandemic led to the deaths of more than 13,500 Australians at the time of publication and cost the nation's GDP an estimated \$144 billion dollars between December 2019 and March 2022.

The CSIRO's Dr Michelle Baker said that "the ability of infectious diseases to spread into pandemics depends on society's response".

"The science and technologies highlighted in Strengthening Australia's Pandemic Preparedness point to innovative ways to improve Australia's resilience," Dr Baker said.

"As Australia's national science agency, CSIRO is focused on partnering with government, industry and the research sector to protect Australia and ensure we are prepared for future pandemics," Dr Baker said.

A CSIRO spokesperson told Biotech Daily that a separate report 'Infectious disease resilience - Co-developing a national Mission, 2021' discussed the impact of climate change on infectious diseases.

The report is available at: <https://bit.ly/3KCljUf>.

RESAPP HEALTH

Resapp says it has its first significant revenue of \$2,512,411, with net loss after tax up 4.7 percent to \$7,095,510.

Resapp said that the majority of its revenue related to Pfizer's pending acquisition of the company, with the remaining revenue from contracts for its Resappdx smartphone-based cough-diagnostic test.

Earlier this month, the company said Pfizer Australia had declared that the 20.8 cents a share offer "is its best and final offer" valuing the company at about \$178.7 million, up from the initial offer of 11.5 cents a share (BD: Apr 11, Aug 17, 2022).

Today, Resapp said its diluted loss per share was down 4.6 percent to 0.83 cents, with net tangible asset backing per share down 80.0 percent to 0.14 cents.

The company said it had cash and cash equivalents of \$2,290,552 at June 30, 2022, compared to \$6,587,434 at June 30, 2021.

Resapp was unchanged at 19 cents with 20.0 million shares traded.

MEDICAL DEVELOPMENTS INTERNATIONAL

Medical Developments says it had bids for about \$2.2 million in its underwritten, \$10 million one for 9.5 retail rights offer at \$2.00 a share, taking the total raised to \$30 million. Earlier this month, Medical Developments said it had raised \$20 million in institutional offer and placement (BD: Aug 8, 2022).

At that time, the company said the offer price was a 16.4 percent discount to the 10-day volume-weighted average price to August 3, 2022, with one option attaching to every 2.5 shares acquired under the capital raising, exercisable at \$2.80 by September 30, 2024.

Today, Medical Developments said it issued about 1.1 million shares or 21 percent of the retail offer, with the shortfall to be taken up by underwriter Bell Potter Securities.

Medical Developments fell 2.5 cents or 1.4 percent to \$1.73.

TOTAL BRAIN

Total Brain says it has a loan from acquirer Sondermind Inc for up to \$US1.75 million (\$A2.54 million), at a yearly 3.5 percent interest rate.

Earlier this month, Total Brain said the Denver, Colorado-based Sondermind would buy it for \$US10 million, pending shareholder approval (BD: Aug 5, 2022).

At that time, the company said that Sondermind would pay Total Brain \$US10 million less any debt it provided Total Brain until the completion of the transaction.

Total Brain fell 0.8 cents or 16.7 percent to four cents.

IMMUTEP

Immutep says a Japan patent has been granted, relating to cancer treatment with eftilagimod alpha, efti or IMP321, and an anti-programmed cell death-ligand 1 antibody.

Immutep said the Japanese Patent Office granted the patent, titled 'Combined Preparations for the Treatment of Cancer or Infection', which would protect its intellectual property until January 8, 2036.

Immutep was up half a cent or 1.8 percent to 28.5 cents with 2.1 million shares traded.

PATRY'S

Patrys says its contract development manufacturing organization has completed testing of PAT-DX1 drug, passing all specification requirements.

Patrys said that good manufacturing practice-grade material could be used to complete remaining pre-clinical toxicology studies for its phase I clinical trial expected by the end of 2023.

Patrys was up 0.1 cents or four percent to 2.6 cents with 3.8 million shares traded.

LUMOS DIAGNOSTICS

Perennial Value Management says it has reduced its substantial holding in Lumos from 18,476,450 shares (8.80%) to 15,455,135 shares (7.36%).

The Sydney-based Perennial said that it sold shares between August 9 and 29, 2022, with the single largest sale on August 9 of 745,382 shares for \$41,278 or 5.5 cents a share.

Lumos was up 0.1 cents or 1.85 percent to 5.5 cents.

OPTHEA

Regal Funds management says it has increased and been diluted in Opthea from the equivalent of 66,771,342 shares (18.96%) to 72,389,923 shares (17.88%).

Regal Funds said it was diluted due to an issue of 52,822,881 shares on August 25, 2022.

Earlier this month, Opthea said it expected to raise \$US263.5 million (\$A370.6 million) through a \$US170 million 'non-dilutive' facility, a \$US90 million placement, and a \$5 million share plan".

Today, Regal Funds said it bought and sold share between June 16 and August 25, 2022, with the single largest purchase on August 25 of 5,552,989 shares for \$6,385,937 or an average of \$1.15 a share.

Opthea fell 1.5 cents or 1.3 percent to \$1.12.

PARADIGM BIOPHARMACEUTICALS

Paradigm says long-serving company secretary Kevin Hollingsworth died last week, and that Abby Macnish has been appointed interim company secretary.

Paradigm said it "wishes to acknowledge Kevin's contribution and passion for Paradigm - and expresses its sincere condolences to the Hollingsworth family".

A Paradigm spokesperson told Biotech Daily that Mr Hollingsworth had been with the company since its inception and ASX-listing in 2014.

The company said Ms Macnish would be its company secretary for a period of nine to 12 months or until a full-time appointment was made.

Paradigm said that Ms Macnish was currently the chief financial officer and company secretary for two ASX-listed companies, as well as a director of biotechnology and wealth management companies.

The company said that Ms Macnish held a Bachelor of Science and a Bachelor of Commerce from the University of Western Australia in Perth.

Paradigm fell half a cent or 0.4 percent to \$1.265.

IMPEDIMED

Impedimed says it has appointed Jan West as non-executive director, effective today, with five-year director Judith Downes to retire at its annual general meeting.

Impedimed said that Ms West had been a non-executive director of Deloitte for more than 20 years, and recently was a director of Australia Post, Australian Red Cross Society, Neurosciences Victoria and Dairy Australia.

Impedimed was up 0.2 cents or 2.9 percent to seven cents.

CYNATA THERAPEUTICS

Cynata says it has appointed Janine Rolfe as a non-executive director, effective from September 1, 2022.

Cynata said that Ms Rolfe had more than two decades of experience in legal, governance and management, most recently working as general counsel and company secretary of Link Administration Holdings, and prior to that founded Company Matters Pty Ltd, and worked for Qantas and Mallesons Stephen Jaques.

Cynata was unchanged at 35 cents.